Incretins and Metabolism

Rigshospitalet

Status: Completed

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Other

Identifiers

NCT01607944

NNF2012

Details and patient eligibility

About

Incretin hormones (GLP-1 and GIP) have insulin secretory effects on the pancreas that are glucose dependent. Extrapancreatic effects of incretin hormones are reported, however the glucose dependency of these effects have not been examined. In type 2 diabetes, pancreatic endocrine function and incretin metabolism are impaired. The investigators hypothesize that extrapancreatic effects of incretin hormones are glucose depedent and dysregulated in subjects with type 2 diabetes.

Healthy control subjects and type 2 diabetics will undergo pancreatic clamps. In brief, somatostatin will be infused to inhibit pancreatic endocrine function and basal levels of insulin, glucagon, and growth hormone will be replace via infusion. Metabolic flux will be studied during euglycemic and hyperglycemic stages of the pancreatic clamp. Each subject will undergo 3 trials involving the co-infusion of either saline(Control Trial), GLP-1, or GIP. Glucose metabolism will be assessed using 13C-glucose stable isotope methodology combined with indirect calorimetry and expired breath isotope ratio analysis. Blood flow and flow-mediated dilation will be measured using ultrasound Doppler. Skeletal muscle and abdominal adipose biopsies will be taken to examine intracellular signalling.

Enrollment: 20 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18-60 years
• BMI 18-35 kg/m2
• NGT or T2DM as classified by ADA criteria

Exclusion criteria

• Insulin dependency
• Smokers
• History of or presentation with cardiovascular disease, cancer, and chronic hematological, renal, hepatic, pulmonary disease
• Weight loss (>2 kg in previous 6 months)
• Physical activity (>150 mins/week)

Trial design

20 participants in 2 patient groups

Normal Glucose Tolerance

Type 2 Diabetes